Didronel
(Etidronate)Phase 2Small molecule
Didronel is one of 77 small molecule programs targeting Calcification. It is currently in Phase 2.
2
Indications
4
Total Trials
2
Active Trials
76
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
341 competitors in Esophageal Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Eloxatin
TevaPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Paraplatin
AAvyxa
Phase 3
Keytruda
Merck & Co.Phase 3
Adrucil
EElorac, Inc.
Phase 3
Camptosar
PfizerPhase 3
Taxotere
AAvyxa
Phase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Calcification2 trials
Esophageal Cancer1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
DIDRONEL
NDA NDA017831
Apr 20, 1987
DIDRONEL
NDA NDA019545
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Etidronate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details